NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from. to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 1990;2021(398):957–80.
Burke AP, Farb A, Liang YH, Smialek J, Virmani R. Effect of hypertension and cardiac hypertrophy on coronary artery morphology in sudden cardiac death. Circulation. 1996;94:3138–45.
Bombelli M, Facchetti R, Carugo S, Madotto F, Arenare F, Quarti-Trevano F, et al. Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values. J Hypertens. 2009;27:2458–64.
Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561–6.
Climie RE, Schultz MG, Fell JW, Romero L, Otahal P, Sharman JE. Central-to-brachial blood pressure amplification in type 2 diabetes: a systematic review and meta-analysis. J Hum Hypertens. 2019;33:94–105.
Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–13.
Patel A, ADVANCE Collaborative Group, MacMahon S, Chalmers J, Neal B, Woodward M, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet. 2007;370:829–40.
Sundström J, Sheikhi R, Ostgren CJ, Svennblad B, Bodegård J, Nilsson PM, et al. Blood pressure levels and risk of cardiovascular events and mortality in type-2 diabetes: cohort study of 34 009 primary care patients. J Hypertens. 2013;31:1603–10.
American Diabetes Association. 10. Cardiovascular disease and risk management: standards of medical care in diabetes-2021. Diabetes Care. 2021;44(Suppl 1):S125–50.
Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the subcommittee of professional and public education of the American heart association council on high blood pressure research. Hypertension. 2005;45(1):142–61.
Cheng HM, Chuang SY, Wang TD, Kario K, Buranakitjaroen P, Chia YC, et al. Central blood pressure for the management of hypertension: is it a practical clinical tool in current practice? J Clin Hypertens (Greenwich). 2020;22:391–406.
Lee HY, Shin J, Kim GH, Park S, Ihm SH, Kim HC, et al. 2018 Korean society of hypertension guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension. Clin Hypertens. 2019;25:20.
Ohte N, Saeki T, Miyabe H, Sakata S, Mukai S, Hayano J, et al. Relationship between blood pressure obtained from the upper arm with a cuff-type sphygmomanometer and central blood pressure measured with a catheter-tipped micromanometer. Heart Vessels. 2007;22:410–5.
McEniery CM, Yasmin N, Hall IR, Qasem A, Wilkinson IB, Cockcroft JR, et al. Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT). J Am Coll Cardiol. 2005;46:1753–60.
Albaladejo P, Copie X, Boutouyrie P, Laloux B, Déclère AD, Smulyan H, et al. Heart rate, arterial stiffness, and wave reflections in paced patients. Hypertension. 2001;38:949–52.
Kim G, Kim JH, Moon KW, Yoo KD, Ihm SH, Youn HJ, et al. The clinical usefulness of central hemodynamics to evaluate diastolic dysfunction in subjects without hypertension. Clin Interv Aging. 2014;9:527–33.
Fryar CD, Ostchega Y, Hales CM, Zhang G, Kruszon-Moran D. Hypertension prevalence and control among adults: United States, 2015–2016. NCHS Data Brief. 2017;289:1–8.
Lamarche F, Agharazii M, Madore F, Goupil R. Prediction of cardiovascular events by type I central systolic blood pressure: a prospective study. Hypertension. 2021;77:319–27.
Sharman JE, Fang ZY, Haluska B, Stowasser M, Prins JB, Marwick TH. Left ventricular mass in patients with type 2 diabetes is independently associated with central but not peripheral pulse pressure. Diabetes Care. 2005;28:937–9.
Hashimoto J, Ito S. Aortic stiffness determines diastolic blood flow reversal in the descending thoracic aorta: potential implication for retrograde embolic stroke in hypertension. Hypertension. 2013;62:542–9.
Hegab Z, Gibbons S, Neyses L, Mamas MA. Role of advanced glycation end products in cardiovascular disease. World J Cardiol. 2012;4:90–102.
Vergnaud AC, Protogerou AD, Li Y, Czernichow S, Vesin C, Blacher J, et al. Pulse pressure amplification, adiposity and metabolic syndrome in subjects under chronic antihypertensive therapy: the role of heart rate. Atherosclerosis. 2008;199:222–9.
Lee HY, Oh BH. Aging and arterial stiffness. Circ J. 2010;74:2257–62.
Iorga A, Cunningham CM, Moazeni S, Ruffenach G, Umar S, Eghbali M. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. Biol Sex Differ. 2017;8:33.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA. 2002;288:321–33.